MacroArray Technologies (www.macroarraytechnologies) signed a licensing agreement with Abbott (www.abbott.com) for MacroArray’s antibody test for prostate cancer. As part of the agreement, Abbott will develop and market the PCADM-1 test, which is an assay designed to detect the novel PCADM-1 prostate specific protein in urine.

The PCADM-1 gene is characterized as a mutated form of the S2 gene and studies have demonstrated the is over-expressed only in malignant prostate tissue, according to MacroArray Technologies. In blinded studies of 533 patients, results indicated the test has an average sensitivity of 79%, and a specificity of 73% to 100%.








This site uses Akismet to reduce spam. Learn how your comment data is processed.